Advanced search
1 file | 77.63 KB

Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease

Author
Organization

Downloads

  • ESPGHAN12-1045-preview-1.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 77.63 KB

Citation

Please use this url to cite or link to this publication:

Chicago
De Greef, E, I Hoffman, G D’haens, Stephanie Van Biervliet, F Smets, M Scaillon, O Dewit, et al. 2012. “Safety and Cost of Infliximab for the Treatment of Belgian Pediatric Patients with Crohn’s Disease.” In ESPGHAN Update, Abstracts.
APA
De Greef, E, Hoffman, I., D’haens, G., Van Biervliet, S., Smets, F., Scaillon, M., Dewit, O., et al. (2012). Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn’s disease. ESPGHAN Update, Abstracts. Presented at the ESPGHAN Update 2012 : GERD, peptic diesease and Helicobacter pylori.
Vancouver
1.
De Greef E, Hoffman I, D’haens G, Van Biervliet S, Smets F, Scaillon M, et al. Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn’s disease. ESPGHAN Update, Abstracts. 2012.
MLA
De Greef, E, I Hoffman, G D’haens, et al. “Safety and Cost of Infliximab for the Treatment of Belgian Pediatric Patients with Crohn’s Disease.” ESPGHAN Update, Abstracts. 2012. Print.
@inproceedings{3175358,
  author       = {De Greef, E and Hoffman, I and D'haens, G and Van Biervliet, Stephanie and Smets, F and Scaillon, M and Dewit, O and Peeters, Harald and Paquot, I and Alliet, P and Arts, W and Hauser, B and Vermeire, S and Van Gossum, A and Rahier, J-F and Etienne, I and Louis, E and Coche, JC and Mahachie, JJ and Van Steen, K and Veereman, G},
  booktitle    = {ESPGHAN Update, Abstracts},
  language     = {eng},
  location     = {Stockholm, Sweden},
  title        = {Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease},
  year         = {2012},
}